Results: 4

1.
Fig. 2.

Fig. 2. From: Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

NY-ESO-1–specific CD4+ and CD8+ T-cell responses were induced after CTLA-4 blockade. Representative dot plots from four patients (IMF-56, 09–079-10, IMF-28, and 09–079-7) with or without NY-ESO-1 overlapping peptide stimulation. Patient IMF-56 had both NY-ESO-1–specific CD4+ and CD8+ T-cell response; patients 09–079-10 and IMF-28 had only NY-ESO-1–specific CD8+ T-cell response or CD4+ T-cell response, respectively; patient 09–079-7 had neither NY-ESO-1–specific CD4+ nor CD8+ T-cell response.

Jianda Yuan, et al. Proc Natl Acad Sci U S A. 2011 October 4;108(40):16723-16728.
2.
Fig. 3.

Fig. 3. From: Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Four types of NY-ESO-1 immunity integration were detected during ipilimumab treatment. (A) NY-ESO-1–specific CD4+ T-cell response before and after CTLA-4 blockade. (B) NY-ESO-1–specific CD8+ T-cell response before and after CTLA-4 blockade. Category I, 11 of 20 patients had NY-ESO-1–specific CD4+ and CD8+ T-cell response; category II, two of 20 patients had CD8 T-cell response; category III, five of 20 patients had CD4+ T-cell response; and category IV, two of 20 patients had neither CD4+ nor CD8 T-cell response.

Jianda Yuan, et al. Proc Natl Acad Sci U S A. 2011 October 4;108(40):16723-16728.
3.
Fig. 1.

Fig. 1. From: Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Titers in NY-ESO-1–seropositive patients from MSKCC. Reciprocal antibody titers to NY-ESO-1 throughout CTLA-4 blockade treatment in patients experiencing clinical benefit (closed symbols, Left; n = 11) or no clinical benefit (open symbols, Right; n = 10) among 99 patients treated with ipilimumab at MSKCC. The remaining 78 patients did not show significant Ab reactivity against NY-ESO-1 at any time point tested and were considered seronegative (i.e., titers <100). Each symbol represents a patient (Right) at baseline, week 7, and week 12 or 24.

Jianda Yuan, et al. Proc Natl Acad Sci U S A. 2011 October 4;108(40):16723-16728.
4.
Fig. 4.

Fig. 4. From: Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

NY-ESO-1 antigen-specific CD8+ T-cell responses are associated with clinical benefit. Maximal percentage of NY-ESO-1–specific CD4+ IFN-γ+ and CD8+IFN-γ+ T cell at any time point during CTLA-4 blockade treatment in NY-ESO-1–seropositive patients treated with ipilimumab at MSKCC who experienced clinical benefit (closed symbols; n = 11) or no clinical benefit (open symbols; n = 9). Responses were considered positive if at least 0.1%. Each symbol represents a patient (Right). Although the frequency of CD4+IFN-γ+ T-cell responses did not significantly differ in patients with or without clinical benefit (P = 0.285), CD8+IFN-γ+ T-cell response were significantly more frequent in patients who experienced clinical benefit (10 of 11) compared with patients who did not experience clinical benefit [three of nine; P = 0.017, RR = 5.4 (0.9–33.9), two-tailed Fisher test].

Jianda Yuan, et al. Proc Natl Acad Sci U S A. 2011 October 4;108(40):16723-16728.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk